a few T-cells within the infiltrates and strikingly by epithelial cells. Furthermore, RANK-L expression by SGEs in primary cultures was increased after INF-a or IL-10 stimulation.

Conclusions: To our knowledge, this is the first report of a RANK-L contribution to primary Sjögren’s syndrome. These results suggest that RANK-L could be an important actor of ectopic lymphoid neogenesis. RANK-L inhibition might represent, in the future, a relevant immunomodulatory strategy in primary Sjögren’s syndrome.

REFERENCES:

Disclosure of Interest: None declared

FR0287
SEROLOGIC EVIDENCE OF VIRAL REACTIVATION AND INCREASED DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Background: Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease oftentimes characterised by a waxing and waning disease course. However, mechanisms of disease flare remain elusive.

Objectives: This study examined relationships between SLE disease activity, immune pathways, and serologic evidence of viral exposures and reactivation within molecular subsets of SLE patients.

Methods: Serial or single samples of plasma, serum and RNA (n=290) were collected from 184 adult SLE patients who met ACR classification and cohort-matched controls (n=49). Disease activity was assessed by modified SELENA-SLEDAI. Immune pathways were evaluated by modular transcriptional analysis of Illumina Beadchip Microarray gene expression data, as well as by plasma soluble markers (tumor necrosis factor (TNF), IL-1β, interferon γ (IFNγ)). Serologic analysis was performed by ELISA and Western blotting.

Results: A total of 320 samples from 184 SLE patients were analyzed for EBV and CMV seropositivity and antibody concentrations. Among SLE patients compared to controls, EBV-IgG responses were enriched in all SLE molecular subsets (p=0.0021), as were EBV-VCA IgA and EBV-EA IgG antibody responses. In cross comparison between patients and controls, IgG responses against EBV-VCA were nearly universally observed (p=0.019). No differences were noted in CMV or HSV1 seropositivity rates for patients compared to healthy controls. EBV-EA IgG responses are elevated in SLE patients compared to healthy controls (OR=8.82 vs 0.340; p=0.033). SLE patients with serologic evidence of EBV reactivation were more common in SLE patients compared to controls, as measured by antibodies against EBV-EA [IgG (40% vs 13%); OR=4.57, p=0.0006] or EBV-VCA [IgA (36% vs 17%); OR=2.70, p=0.019]. No differences were noted in CMV or HSV1 seropositivity rates between patients and controls. IgG responses against EBV-VCA were nearly universal among these adult patients and controls; however, concentrations of EBV-VCA IgG were higher in SLE patients compared to controls (ISR=4.44 vs 3.52; p=0.0021), as were EBV-VCA IgG and EBV-EA IgG antibody responses. In cross sectional analysis, SLE patients with higher disease activity (SLEDAI ≥ 6; n=126) had higher concentrations of EBV-EA IgG than patients with lower (≤166) disease activity (ISR=0.822 vs 0.540; p=0.033). SLE patients with serologic evidence of EBV reactivation by EA IgG responses had higher levels of interferon associated molecules, IP10 (p=3.4×10^-7), BLyS (5.5×10^-5), and IL-10 (p=0.00013). HSV1 IgG positive SLE patients also showed higher levels of IP10 (2.2×10^-7). Antibody responses toward EBV-EA were enriched in molecularly defined patient clusters with higher expression levels of interferon and inflammatory modules, as well as with interferon and inflammatory soluble mediators. Patients within these clusters were also more likely to have major organ involvement, such as renal or neurologic disease.

Conclusions: Serologic evidence of EBV reactivation is more common in SLE patients compared to healthy controls. EBV-EA IgG responses are elevated in SLE patients with active disease and correspond with increases in interferon-associated mediators. This study provides serologic evidence suggesting a possible role for viral reactivation in SLE disease activity.

Acknowledgements: This work was supported in part by grants from the National Institutes of Health: U19AI082714, U01AI101934, U54GM104938, P30AR053483, R01AR072401. Disclosure of Interest: None declared

FR0288
THYMIC STROMAL LYMPHPOIETIN (TSLP)
BIOLOGICAL EFFECTS ON HUMAN PERIPHERAL BLOOD B LYMPHOCYTES IN PRIMARY SJÖGREN’S SYNDROME
S. Gandolfo1, M. Bulloni2, C. Fabro1, E. Dorizzi Breatta1, L. Quattrocchi1, C. Di Loreto3, D. Cesselli4, S. De Vita1. 1Clinic of Rheumatology, University Hospital of Udine; 2Institute of Anatomic Pathology, University Hospital of Udine, Udine, Italy;
3Department of Radiological, Oncological and Pathologic Sciences, Sapienza Università Di Roma, Rome, Italy; 4Centre for Translational Inflammation Research, University of Birmingham, Birmingham, UK.

Background: Thymic stromal lymphopoietin (TSLP) is an epithelial lymphoid-poitic cytokine belonging to interleukin (IL)-7 family, acting as a B-cell growth factor. A pathogenic role of TSLP in primary Sjögren’s syndrome (pSS) and pSS-related B-cell lymphoproliferation has been recently indicated. 

Objectives: to investigate the biological effects of TSLP on human peripheral blood B lymphocytes in pSS.

Methods: Peripheral blood B lymphocytes from 15 pSS patients, stratified according to their lymphoproliferative status (fully benign, bSS; n=5; myoepithelial lial sodaialtis, MESA; n=5; B-cell non-Hodgkin lymphoma, NHL; n=5) and from 5 healthy blood donors (HBDs) were isolated by immunomagnetic negative selection and cultured with three different stimuli: 1) TSLP, ii) combination of TSLP and IL-4, iii) combination of CD40 functional grade monoclonal antibody and IL-4. B-cell activation status was evaluated by flow cytometry and expression of surface IgM after stimulation. An ELISA assay was also performed to assess the immunoglobulins (Ig) production in the B-cell culture supernatants after the exposure to three different stimuli.

Results: peripheral blood B lymphocytes isolated from bSS patients were significantly activated by the combination of TSLP and IL-4 (p=0.0218), as well as by the classic co-stimulation of anti-CD40 plus IL4 (p=0.004). Unexpectedly, the combined stimulus of TSLP plus IL4 did not produce any significant effect in both these subgroups, and was less effective than TSLP alone also in stimulating B-cell surface IgM expression.

Conclusions: human peripheral blood B-cells from pSS patients showed an increased responsiveness to TSLP, however with significant differences. In HBDs and in bSS, TSLP induced a significantly higher B-cell activation and immunoglobulin production only with the addition of IL4, whereas in NHL alone TSLP was sufficient. In addition, IL4 co-stimulus induced a lower activation than the expression of surface IgM after stimulation. An ELISA assay was also performed to support a role of TSLP as an important driver of B-cell stimulation and lymphoma progression in pSS. Interactions of TSLP with other B-cell stimulating factors also deserve particular attention.

REFERENCE:

Disclosure of Interest: None declared

FR0289
ROLE OF CXCL13 AND CXCL12 IN SJÖGREN’S SYNDROME: ASSOCIATION WITH HISTOLOGICAL, CLINICAL AND LABORATORY FEATURES
S. Colafrancesco1, R. Prioli2, E. Pipì3, J. Camposi3, S. Nayyar3, B. Cerbetti5, F. Arlenzo1, C. Giordano5, M. Llybard5, G. Valesini1, F. Barone1. 1Dipartimento di medicina interna e specialità medico, SAPIENZA UNIVERSITÀ DI ROMA, Rome, Italy; 2Centre for Translational Inflammation Research, University of Birmingham, Birmingham, UK; 3Department of Radiological, Oncological and Pathological Sciences, Sapienza Università Di Roma, Rome, Italy; 4Department of Experimental Medicine and Rheumatology, Barts and the London NHS Trust and Barts and the London School of Medicine and Dentistry, University of London, London, UK.

Background: Ectopic production of the lymphoid chemokines CXCL13 and CXCL12 has been described in tertiary lymphoid structures (TLS) that harbour in the salivary glands of patients with Sjögren’s Syndrome (pSS). Whilst CXCL13 expression correlates with clinical features, its potential role as a biomarker to
monitor the organization and severity of the salivary gland infiltrate has been hampered by the lack of sensitive tools to describe TLS extent and features.

**Objectives:** To investigate CXCL13 and CXCL12 serum and tissue expression and to find any possible association with clinical, histological and laboratory features.

**Methods:** We studied histological features of the minor salivary glands (MSG) and sera of respectively fifty and seventy (table 1) unselected consecutive patients with pSS (AECG criteria). Concentration of CXCL13 and CXCL12 were evaluated by ELISA in patient sera and eleven healthy controls (HC). Paraffin embedded MSG were studied by haematoxylin/eosin and anti-CD3, anti-CD20, anti-CD21 staining. Images analysis was used to calculate focus score (FS), mean foci area, percentage of infiltration (%i), segregated foci (%SF),%GCs and lymphoepithelial lesions (%LEL). GCs from MSG and tonsils were microdissected and quantitative PCR was used to test CXCL12 and CXCL13 transcripts.

**Results:** Histological analysis unveiled strong correlations between the mean foci area with the% and the presence of SF; positive correlations were also observed between the% and both the FS and%SF. This was significantly higher in patients exhibiting SF. The% of SF positively correlated with FS, presence of% GC and%LEL that also correlated with the% and the%SF (image). Mean CXCL13 and CXCL12 serum levels were significantly higher in pSS compared to HC [(124.12±119.73 pg/ml vs 8.9±15.4 pg/ml (p=0.001) and 34.6±54.2 pg/ml vs 2.5±8.3 pg/ml (p=0.05), respectively)]. CXCL13 was significantly higher in patients with SF, with GCs and LEL and correlated with the mean foci area, the%, the FS and the percentage of LEL. Higher CXCL13 levels were also able to discriminate patients with lymphoma (p=0.009). CXCL12 levels correlated with the% SF, the% and% of LEL. Transcript analysis showed no difference in the expression of CXCL13 between MSG and tonsils, GC, whilst CXCL12 was found significantly higher in MSG (p=0.0001).

**Conclusions:** Our results suggest the utility to expand the parameters of histologic evaluation of MSG, whilst reinforcing the role of the FS as reliable instrument to reflect the severity of inflammation. Analysis of MSG infiltration and foci segregation was able to identify subjects with increased proliferative risk. We demonstrated that serum CXCL13 is a biomarker of histological severity and is able to stratify patients with lymphoma. The high levels of CXCL12 in MSG GC suggest a differential biology of TLS in the SG, probably implicated in aberrant B cell clone survival.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.5192

---

**FRI0290**

**PRO-INFLAMMATORY CYTOKINES PROMOTE GLOBAL AND GENE-SPECIFIC CHANGES IN DNA METHYLATION IN SALIVARY GLANDS FROM SjÖGREN’S SYNDROME PATIENTS**

**C. Lagos1, S. Aguílara2, P. Carvajal2, D. Jara1, I. Castro1, S. González1, U. Urua1, M.J. Barrera3, C. Molina4, C. Leyton5, M.J. González1. 1ICBM, Facultad de Medicina, Universidad de Chile; 2Reumatología, Clínica INDISA; 3Patología Oral, Universidad Mayor, Santiago, Chile**

**Background:** Salivary glands (SG) from Sjögren’s syndrome (SS)-patients show chronic inflammation and altered unfolded protein response (UPR). Pro-inflammatory cytokines induce epigenetic changes including DNA methylation, a dynamic and complex process where cytosines of CpG sites are methylated (5mC) by DNA methyltransferases (DNMT), and then hydroxymethylated (5hmC) by TET enzymes.

**Objectives:** To determine DNA methylation in promoters of specific UPR genes and levels of 5mC, 5hmC, DNMT and TET enzymes in labial-SG from SS-patients and cytokines effects on global DNA methylation and DNA methylation of specific gene promoters in human SG cells.

**Methods:** SG biopsies from 23 SS-patients and 15 controls were analysed. 5mC and 5hmC levels were assessed by immunofluorescence (IF), quantified independently in epithelial and inflammatory cells and correlated with focus score, mRNA levels of DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b), and dioxygenases TET1, TET2 and TET3 were performed by qPCR. The in situ protein levels of these enzymes were evaluated by IF. Specific DNA methylation of IRE1α, XBP-1, GRP78, ATF4 and ATF6α promoters was evaluated by MS-HRM. Human SG cells (HSG) and 3D-ascini were incubated with 1 or 10 ng/mL TNF-α and IFN-γ for 24 hour. Levels of 5mC, 5hmC, methylation of specific gene promoters and transcript levels of UPR molecules, DNMTs and TETs were measured by qPCR.

**Results:** LSG epithelial cells from SS-patients showed significant increase of DNA hydroxymethylation and decrease of DNA methylation. Their 5hmC levels were positively and 5mC levels inversely correlated with focus score. Inflammatory cells showed high levels of 5mC and DNMTs and low levels of 5hmC. Increased mRNA levels of DNMT1, DNMT3a, and TET2 and a significant decrease of TET1 and TET3 were observed. Protein levels of TET2 were significantly higher in LSG epithelial cells from SS-patients. The above results were reproduced in HSG cells where cytokine stimulation increased TET2 and 5hmC and decreased 5mC levels. SS-patients SG and 3D-ascini stimulated with cytokines, revealed an inverse correlation between gene promoter DNA methylation and transcript levels of IRE1α, XBP-1, GRP78, ATF4 and ATF6α.

**Conclusions:** Pro-inflammatory cytokines promoted increase of 5hmC and decrease of 5mC in SG epithelial cells likely by inducing TET2 expression. Global DNA hypomethylation have also been observed in other autoimmune diseases, where some specific genes appear to be hypermethylated. Our results showed a concordance between the methylation of UPR gene promoters and its transcriptional regulation, which was modulated by cytokines. High DNMTs protein levels observed in inflammatory cells are consistent with high levels of 5mC suggesting functional regulation, which was modulated by cytokines. High DNMTs protein levels were positively and 5mC levels inversely correlated with focus score. Inflammatory cells showed high levels of 5mC and DNMTs and low levels of 5hmC. Increased mRNA levels of DNMT1, DNMT3a, and TET2 and a significant decrease of TET1 and TET3 were observed. Protein levels of TET2 were significantly higher in LSG epithelial cells from SS-patients. The above results were reproduced in HSG cells where cytokine stimulation increased TET2 and 5hmC and decreased 5mC levels. SS-patients SG and 3D-ascini stimulated with cytokines, revealed an inverse correlation between gene promoter DNA methylation and transcript levels of IRE1α, XBP-1, GRP78, ATF4 and ATF6α.

**Acknowledgements:** Fondecyt-Postdoctorado-3170023, MJB.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.3784